Specialized heart-protection clinic for people with diabetes and heart or vessel disease
Tests a specialized Cardio-Metabolic Clinic against usual care in adults with diabetes and heart disease.
Plain-language title generated from the registry record
Registry title: The Cardio-Metabolic Clinic
Key facts
- Where
- Svendborg, DenmarkSee the site
Where in Denmark
- Cardiovascular Research Unit, Odense University Hospital - SvendborgSvendborg, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Odense University Hospital
- Trial code
- NCT06203860
- Record updated
- 8 July 2025
- Original description
This study aims to investigate whether a Cardio-Metabolic Clinic can protect the cardiovascular health of patients with both diabetes and cardiovascular disease.Read full original descriptionShow less
Cardiovascular Protection in Patients With Type 2 Diabetes and Established Heart or Vascular Disease - The Cardio-Metabolic Clinic
This study aims to investigate whether a Cardio-Metabolic Clinic can protect the cardiovascular health of patients with both diabetes and cardiovascular disease.
* At the Cardio-Metabolic Clinic, patients will receive a specialized and comprehensive care. This includes applying a systematic approach, considering their whole health based on the latest knowledge in the field, and administering aggressive treatment with heart protective medications. * The ProtecT-2-D trial will compare the effects of care at the Cardio-Metabolic Clinic to usual care to see if there are any differences in cardiovascular illness and death.
Inclusion:; >18 years; Capable of giving written informed consent; Established diagnosis of T2D; Having established heart or vascular disease defined as either:; Atherosclerotic disease defined as:; Prior acute coronary syndrome (ACS); Chronic coronary syndrome defined as the combination of: Angina pectoris AND coronary atherosclerosis assessed with either Coronary CT angiography (CTA) or Myocardial-scintigraphy (MPI) or Coronary angiography (CAG) AND treatment with statins and/or acetylsalicylic acid; Stroke; Peripheral arterial disease (PAD) defined as: Claudication intermittence in combination with pathological ABI AND/OR vascular PAD surgery AND/OR ischemic amputation; Ischemic heart disease defined by one of the following criteria: a) Myocardial-scintigraphy: >10% reversibility OR b) Coronary CT angiography: Coronary Artery Calcium (CAC)-score >100; Heart failure (HF): HF with reduced ejection fraction (HFrEF), HF with Mildly reduced ejection fraction (HFmrEF), HF with preserved ejection fraction (HFpEF); Atrial fibrillation and/or flutter, including paroxysmal, persistent and chronic disease; Valvular heart disease (which requires control in outpatient clinic of cardiology), such as aortic valve stenosis, mitral valve insufficiency, and patients with aortic dilatation; Hypertension treated with at least three antihypertensive drugs; Exclusion:; Life expectancy less than 5 years for any reason; Type 1 Diabetes Mellitus; Participation in another clinical trial with an investigational product or device that could interfere with the primary and/or secondary endpoints of this study.